Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Jingwen Wang, Weili Zhao et al.|Journal of Hematology & Oncology|2017Cited by 256
Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomibLi Xu, Xiequn Chen|Cell Death and Disease|2020Cited by 23
The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma EffectsHong-Yuan Shen, Xiequn Chen|Journal of Oncology|2022Cited by 22